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Abstract 
Finding, testing and demonstrating efficacy of new treatments for stroke recovery is a 
multifaceted challenge. We believe that to advance the field, neurorehabilitation trials need a 
conceptually rigorous starting framework. An essential first step is to agree on definitions of 
sensorimotor recovery and on measures consistent with these definitions. Such standardization 
would allow pooling of participant data across studies and institutions aiding meta-analyses of 
completed trials, more detailed exploration of recovery profiles of our patients and the 
generation of new hypotheses. Here, we present the results of a consensus meeting about 
measurement standards and patient characteristics that we suggest should be collected in all 
future stroke recovery trials. Recommendations are made considering time post stroke and are 
aligned with the international classification of functioning and disability. A strong case is made 
for addition of kinematic and kinetic movement quantification. Further work is being 
undertaken by our group to form consensus on clinical predictors and pre-stroke clinical data 
that should be collected, as well as recommendations for additional outcome measurement 
tools. To improve stroke recovery trials, we urge the research community to consider adopting 
our recommendations in their trial design. 
Introduction  
Lack of a standardized approach to measurement in stroke recovery research hampers our 
ability to advance understanding of recovery mechanisms, devise better treatments and 
consolidate knowledge from a body of research using meta-analyses.1 As examples, 
examination of a recent Cochrane Overview of interventions to improve upper limb function 
after stroke identified 208 unique assessment tools from 243 trials2 ; another review found 
more than 100 measures of activities of daily living (ADLs).3 Furthermore, in most motor 
rehabilitation trials, measures are taken at arbitrary time points relative to stroke onset, e.g. 
time of admission to, or discharge from, rehabilitation rather than at standard time points 
aligned with underlying recovery processes.4  
We must challenge the common assumption that most sensorimotor therapies are universally 
applicable and will achieve the same benefit for all people with stroke. The magnitude of 
change and likelihood of achieving clinically meaningful improvement in response to specific 
therapies will depend on age, stroke severity, and other factors including pre-existing comorbid 
conditions (e.g. diabetes, cognitive impairment, depression)5 and pre-stroke lifestyle factors 
(e.g. social engagement, exercise).6 The respective contributions of these factors have yet to 
be fully understood. Going forward, we need to identify the determinants that may help predict 
responders and non-responders to interventions.  
The measurement working group of the Stroke Recovery and Rehabilitation Roundtable 
(SRRR)7 was established to develop recommendations for standardized assessment time points 
and measures to be included in all adult trials of sensorimotor recovery after stroke. Given the 
current lack of standards for data collection and heterogeneous reports in stroke recovery trials, 
our expert group also considered prestroke clinical, demographic and stroke-related data that 
should be collected to improve clinical prediction of recovery and characterization of patient 
cohorts.  
The decision to focus on sensorimotor recovery reflects the volume of existing trials in this 
area, the range of outcomes currently in use across these trials, and the gap in current research 
that known international initiatives has not addressed (e.g. Core Outcome Measures in 
Effectiveness Trials Initiative (COMET), National Institute of Neurological Disorders and 
Stroke Common Data Elements (NINDS CDE), The International Consortium for Health 
Outcomes Measurement (ICHOM),8 Improving Research Outcome Measurement in Aphasia 
(ROMA)9 and Standardization of Measures in Arm Rehabilitation Trials after Stroke 
(SMART), Supplementary Table 1). Acknowledging that clinical measures cannot distinguish 
between true neurological repair (behavioral restitution) and use of compensatory strategies,10 
a second objective was to consider whether we could recommend specific kinetic and/or 
kinematic outcomes that reflect quality of motor performance in order to better understand the 
neurophysiological changes that occur when patients improve.11,12 Our overall objective of 
the roundtable was to provide recommendations that, if applied, could improve the 
methodology of rehabilitation and recovery trials, help build our understanding of the trajectory 
of stroke recovery and aid discovery of new and more targeted treatments. 
Methods  
This consensus generating initiative was registered with the COMET group 
(http://www.comet-initiative.org/ studies/details/910).  
Development of core measurement set  
Over five stages (Figure 1), our expert group developed the core measurement set. A ‘core’ 
measure was considered one that should be included in all stroke rehabilitation and recovery 
trials.  
Stage 1. Establish measurement time point recommendations based on neural repair 
processes.13 The SRRR definitions paper contains rationale for time points and description of 
terms.10  
Stage 2. Selection of stroke impairment constructs (sensorimotor, quality of life and global 
disability) and measurement tools (n ¼ 72), identified through expert group survey and scoping 
of existing recommendations and resources (Supplementary Table 1).  
Stage 3. Identification of desirable characteristics of a ‘‘good’’ measurement tool using 
Keeney’s Value Focused Thinking Methodology.14 Via survey, the expert group elicited 19 
desirable properties that subsequently formed six categories: (1) relevance of intended purpose 
to intended use; (2) responsiveness and sensitivity; (3) reliability; (4) feasibility; (5) ability to 
run meaningful statistical analysis; and (6) relevance to the International Classification of 
Functioning and Disability model (ICF model). The expert group members then ranked these 
six categories in order of importance for appropriate outcome measurement in clinical trials of 
stroke recovery and rehabilitation. We implemented a structured process used by Utley et al.15 
that aggregated rank-ordered lists produced by individual experts using a robust graph theory-
based voting system as a decision-support tool in Microsoft Excel, and this was used to form a 
prioritized list for the expert group.  
Stages 4 and 5. Respondents reviewed source documents pertaining to each tool and then 
ranked each measurement tool within each construct, considering how each tool overall met 
the desirable properties at each measurement time point, and elected whether the tool should 
be a core measure for that time point. For every individual construct at every given time point, 
Utley et al.15 process was adopted to aggregate ranked lists by individual experts into a ranked 
list of preferred tools for the expert group.  
Stage 6. Face-to-face discussion occurred at SRRR to finalize consensus on core measurement 
recommendations. Recommendations were reported back to the entire SRRR group (n ¼ 60) 
for comment.  
With consensus on measurement tools established, we then synthesized the consensus-based 
standards for the selection of health status measurement instruments (COSMIN) ratings, which 
evaluated the methodologic quality of the recommended outcome measures.16  
Standardized patient and stroke data.  
To meet our objectives for recommendations to include standards for collection of baseline 
patient and stroke related data, including clinical predictors of recovery such as prestroke data 
relevant to how well a person with stroke may engage in rehabilitation, small groups of three 
to five people reviewed the literature relevant to the area under consideration. These data were 
presented to the expert group at the SRRR meeting for consideration. 
 
Stage 1
· Definition of 5 key measurement time points based on neurobiological repair processes
· Undertaken by expert opinion of SRRR steering committee {ref definitions paper}
Stage 2 · Identification of measurement tools from external groups'  recommendations and expert group opinion
· Selection of 72 measurement tools covering 8 sensorimotor constructs  
Stage 3 · Individual experts  nominate desirable properties of measurement tools
· Individual experts rank relative importance of groups' list of desirable properties of measurement tools
· Produce the expert group aggregated list of desirable properties of measurement tools 
Stage 4
· Individual experts rank measurement tools for every time point, within every construct, considering all 
desirable properties.
Stage 5 · Produce the expert group aggregated list of ranked measurement tools
Stage 6 · Generate consensus about selection of core measures by discussion of ranked list at roundtable meeting 
 
Figure 1 Stages to develop consensus on core measurements 
Results  
Core outcomes 
Box 1 summarizes the general recommendations for measurement in stroke recovery trials. 
Wherever possible, researchers wishing to test interventions aimed at sensorimotor recovery 
should commence assessment within seven days of stroke onset, then at set time points up to 
at least three months post stroke. Note that regardless of when the intervention ends, and the 
choice of primary endpoint, three month assessment is recommended for all trials. Additional 
time points may be selected as relevant for a specific research question. For trials testing 
interventions more likely to work at the level of behavioural compensation, that typically 
commence later post stroke, acquisition of stroke severity at stroke onset, as well as at time of 
recruitment to trial, is still strongly recommended.  
Core measures (Table 1, Supplemental Table 2), standard demographics and stroke data (Box 
1) should be gathered in all trials. Having evaluated the performance of each measure at each 
time point, some core measures are not required/relevant at certain time points. COSMIN 
ratings for each of the recommended outcome measures are shown in Supplementary Table 3. 
Stroke severity should be assessed using the National Institutes of Health Stroke Score 
(NIHSS), but we recommended the NIHSS not be used as a measure of recovery. Additional 
outcome measures, aligned with the trial purpose and target intervention can be added. We 
could not reach consensus on a participation measure, all exhibited generally inadequate 
measurement properties. Consensus-based recommendations for additional stroke measures, 
including sensory measures, will be available in future from the SRRR group (work in 
progress).  
Patient demographics, pre-stroke data and baseline data 
Due to the limited time available at the SRRR meeting, a formal consensus approach to 
determine a standard collection of demographic, pre-stroke or clinical prognostic data was not 
possible. After small group review and post meeting discussion, recommended patient 
demographics and baseline data to be included in all trials are shown in Box 1. Considerations 
for these recommendations are as follows: Patient-level data are used to characterize the study 
population, enable exploration of factors that may influence recruitment, retention and response 
to intervention and allow later data pooling with similar studies, at an individual or group level. 
Baseline patient level data are also used for stratification (i.e. to assign patients with similar 
potential for recovery to groups at randomization to ensure that treatment groups are 
balanced.5,17–19 Several prognostic tools developed to determine risk of recurrent stroke and 
clinical outcomes (e.g. death, disability, and discharge destination) are considered as a valuable 
approach for selecting or monitoring acute trial participants (see Supplemental Table 4 for 
summary of tools).20–23 In stroke recovery trials, we have yet to determine the important 
clinical biomarkers of stroke recovery.24 Age and initial stroke severity are the strongest 
predictors of outcome after acute stroke. Some comorbid conditions have also been associated 
with poorer stroke recovery (e.g. heart failure, chronic kidney disease, diabetes, atrial 
fibrillation). In addition to the presence of chronic diseases,25,26 social and lifestyle factors, 
psychological, cognitive and physical factors7 may impact post-stroke recovery trajectories. 
Patients’ medical histories usually include presence of comorbidities, living arrangements pre-
stroke, degree of social support, occupation and lifestyle factors. Additional factors such as 
pre-existing depression or mood disorders which are associated with poorer outcome6 are often 
ascertained via routine screening procedures in clinical practice and should also be considered 
in our trials.  
Cognitive reserve (the ability to cope with brain damage) is one mechanism postulated to 
explain differences in functional ability in patients with similar degrees of brain damage.27 
However, we currently lack an adequate measure of cognitive reserve for use in stroke trials. 
Level of education is a marker for prestroke cognitive function and has a role in determining 
cognitive outcomes in people with vascular dementia; it is similarly associated with aphasia 
severity and long-term survival after stroke, so we recommend its inclusion here. While the 
association between physical activity and stroke risk is established,28,29 we found conflicting 
evidence about the impact of pre-stroke physical activity on stroke severity and outcome. The 
estimation of pre-stroke physical activity is difficult as self-reported measures are inaccurate, 
use of the question ‘‘How often do you exercise vigorously enough to build up a sweat?’’ is 
only moderately correlated with objective measures of fitness, and more general physical 
activity questionnaires are inadequate.30 At this stage, we could not recommend inclusion of 
a specific prestroke measure of physical activity; however, validation of such measures should 
be a priority. Active hand movement and walking at admission (items 10 and 11 in Box 1) are 
recommended particularly in trials that commence later post stroke where NIHSS at stroke 
onset could not be gathered. These ‘simple questions’ of baseline performance are included in 
a number of stroke registries because they are associated with outcome. They may be helpful 
in retrospective data pooling or analysis. 
 Box 1: Consensus based recommendations for measurement in stroke recovery & rehabilitation trials 
Recovery trials are designed to examine the natural recovery trajectory and/or assess the comparative effectiveness of intervention(s) 
aimed at biological restitution. Rehabilitation is a process of active biological change in the central nervous system by which a person who 
has become disabled acquires the knowledge and skills needed for optimum physical, psychological and social function. SRRR definitions 
paper (1) contains further descriptions. 
1. Time points of applied measurements should always refer to time post stroke onset. 
2. “Stroke onset” refers to within three days of onset of symptoms. 
3. The National Institutes of Health Stroke Scale (NIHSS) should be used to measure ‘baseline’ stroke severity in all trials, regardless of 
when the trial starts*. Individual item and total NIHSS scores should be reported. Where possible, NIHSS should be assessed at stroke 
onset (i.e. within three days of symptoms) for all trials. 
4. For recovery trials, the first outcome assessment should be completed within seven days of stroke onset.  
5. Always include three-month post-stroke assessment points in recovery trials (essential). Consider six months and twelve months 
(especially for health economics). Later time points are dependent on trial design.  
6. Core measures should be collected in every trial. Stroke severity and outcome measures for each time point are included in Table 1, see 
below for standard demographics and stroke data, and Supplementary Table 4 for outcome measure training options and cost 
information. Full measures (not sub-sections) should be collected with exception of the Fugl-Meyer assessment (FMA) for which only 
the motor part is recommended (Table 2).  
7. Adverse events should be pre-specified and collected according to Good Clinical Practice (GCP). 
8. Recovery trials need to consider serially applied kinematic/kinetic measurements alongside clinical assessments to distinguish between 
restitution and compensation. A core set of kinetics and kinematic outcomes needs to be established. 
9. Pre-stroke patient-level data (eg physical activity, cognition): No specific recommendation, but this is considered an important area of 
future enquiry. 
*Note: Stroke severity at onset is an important predictor of outcome, so should be routinely collected. 
Recommendations for demographic and stroke information to collect for all research participants 
1. Age: Years and category: 18 - 55, 56 – 74, >75 years 
2. Sex: Male / Female / Other 
3. Ethnicity: self-description 
4. Medical History 
• Vascular risk factors (coronary artery disease, AF, diabetes,  hypertension, clinical obesity, smoking and alcohol use, 
hyperlipidemia) 
• Renal or cardiac failure 
• Prior stroke or transient ischaemic attack (TIA) 
• Co-morbid conditions (cognitive decline, osteoarthritis, other neurological disease) 
5. Premorbid function: Modified Rankin Scale (mRS) 
6. Education: year count  
7. Premorbid walking status: Independent with or without gait aid / with assistance / unable  
8. Premorbid living arrangements 
• Living alone Y / N 
• Living at home / supported accommodation 
9. Stroke severity:  National Institute of Health Stroke Scale (NIHSS) 
10. Active hand movement at stroke onset? Y / N 
11. Ability to walk independently at stroke onset? Y / N 
12. Stroke type: Ischaemic / Haemorrhage 
13. Stroke sub-type: Lacunar / Large artery / Other (e.g. carotid dissection) / Undetermined  
14. Stroke location: 
• Cortical: Internal Capsule / Middle cerebral artery (MCA) / Frontal lobe 
• Subcortical: Thalamus /  Basal Ganglia 
• Midbrain: Pons / Medulla / Cerebellum 
• Brainstem  
15. Thrombolysis / reperfusion therapy: Y / N 
16. Imaging: 
• Confirmed stroke on imaging Y / N 
• CT obtained Y / N 
• MRI obtained Y / N 
Table 1 Recommendations of core measures to include in every stroke recovery trial 
Time point & 
Measure 
Acute 
7 Days 
Early Sub-acute 
3 months* 
Late Sub-acute 
6 months 
Chronic 
>6 month 
Stroke severity§ NIHSS NIHSS NIHSS NIHSS 
Body function & 
structure 
FM – motor arm & leg FM – motor arm & leg FM – motor arm & leg FM – motor arm & leg 
Activity limitation: 
      Upper limb 
      Walking^ 
 
 
ARAT 
Able to walk 10m 
independently? 
10m walk test 
 
ARAT 
Able to walk 10m 
independently? 
10m walk test 
 
ARAT 
Able to walk 10m 
independently? 
10m walk test 
 
ARAT 
Able to walk 10m 
independently? 
10m walk test 
Quality of Life Consensus agreement:  
Inappropriate to test 
EQ-5D EQ-5D EQ-5D 
Global disability Consensus agreement:  
Inappropriate to test 
mRS mRS mRS 
Participation No consensus¥ 
ARAT = Action Research Arm Test; EQ-5D = self-report questionnaire of health status; FM = Fugl Meyer; ICF = International Classification of 
Functioning and Disability Model; NIHSS = National Institute of Health Stroke Scale; mRS = modified Rankin Scale (NOTE: we recommend use 
of the Simplified mRS in line with ICHOM (9) 
*Include three month assessment in all trials 
§ NIHSS is recommended to classify stroke severity, but not as an outcome measure. 
^ Two core measures of walking are recommended: 1) Can person walk 10 meters independently (gait aids permitted) Y/N? and 2) timed 10  meter 
walk test at comfortable pace if able to walk 10 m independently. For data integrity, do not score (or impute zero) for people who cannot complete 
this test, rather, record unable/not applicable. Therefore, to avoid missing data and preserve validity, for trials with the primary aim of measuring 
the progress in walking we do not recommend 10m walk as a primary outcome measure. For such trials, an alternative measure should be 
considered, e.g. a continuous and fully evaluable primary outcome measure such as 6 minute walk.  
¥ Evidence to support inclusion of any one tool as a core measure was lacking.
Measuring quality of motor performance in stroke recovery trials  
To improve our understanding about the mechanisms that drive motor recovery, we need to 
delineate between ‘true neurological repair’ (i.e. restitution) in which neurological impairments 
are restored towards normal and behavioral compensation strategies.31–33 While clinical 
measures of activity limitations such as the Action Research Arm Test and walking speed can 
measure change, they cannot delineate between restitution and compensation. Technological 
developments in wearable miniaturized sensors, robots and force sensors may make monitoring 
of kinematics and kinetics feasible as additional outcome parameters to objectively measure 
improvement in stroke recovery trials.34,35 While desirable, our group determined that 
reaching consensus with regard to the best kinematic and kinetic parameters to assess 
sensorimotor control was not feasible in the given time frame. That said, we strongly believe 
that kinematic and kinetic measures should be considered essential in future trials and be 
developed accordingly. These tools represent the best way to distinguish behavioral restitution 
from compensation. Below we offer a brief commentary on those measures that look promising 
for upper limb and walking recovery.  
Some recommendations already exist for gait analysis,36 standardization of parameters of 
upper limb coordination of reach to grasp movements37 and upper limb robotics.35 Kinematic 
measures of the movement endpoint, whole trajectories, joint angles as well as correlations 
between key events in the transport and grasp phases of reaching can be used to address 
questions about movement quality after stroke. For example, are patients becoming more 
accurate and less variable? Are trajectories becoming smoother and less curved? Are 
movements beginning to be controlled out of synergy? Depending on how the kinematics is 
analyzed, it is possible to determine whether a given movement is compensatory, for example 
excessive trunk movement, or becoming more similar to a normal movement.31,33,35,38–48 
Kinematic data can be obtained during performance of a specific functional task, for example 
attempting to pick up a glass, or with specially designed non-functional assays, for example 
the finger individuation index using a cyberglove or planar reaching tasks. For both the 
functional tasks and the motor assays, it is possible mathematically to compute a distance 
between a patient’s global kinematic trajectory and a control data set.  
For the lower limb, normalization of the quality of motor performance is strongly reflected by 
measures of inter-limb coordination such as left-right symmetry in spatio-temporal parameters 
of gait, and kinetic parameters such as torque and (ground reaction) forces for establishing the 
(a)symmetry between the hemiplegic and non-hemiplegic side, such as displacement of centre 
of mass while standing49–51 and walking.52 All of these measures are seen as important 
outcomes reflecting the symmetry, and with that, quality of hemiplegic gait performance. 
Recommending specific measures (and methods) for inclusion in trials is challenging. Broader 
collaboration between investigators in similar areas of study to align outcomes is encouraged. 
Discussion  
In our ‘moving rehabilitation research forward’ paper,7 we outlined why standardising 
measurement in trials is important to our field. Over the course of a year, the SRRR 
measurement group undertook extensive literature reviews, consulted with experts in 
measurement and decision analytics and used a pre-defined methodology to achieve consensus 
about a core set of valid measures that should be used in every stroke recovery and 
rehabilitation trial and be assessed at fixed times post stroke. This important step will make 
stroke trials more comparable, irrespective of their results (i.e. negative, neutral or positive). 
The pooled data sets from different trials may allow individual patient-level meta-analyses in 
which responders and non-responders to an intervention can be identified at different recovery 
phases post stroke (see also recommendations from the SRRR intervention group).53 Better 
knowledge of the profiles of patients that benefit most, will not only help in designing better 
trials in terms of adequate stratifi- cation (see for example EXCITE18 and EXPLICIT stroke 
trials19) but will also generate new and better hypotheses about how therapies work at different 
phases post stroke and the underlying mechanisms of recovery.  
We achieved our primary goal of developing the core set and providing guidance about 
standardized demographic and stroke-related data which we recommend to be gathered in all 
trials. We recognize that the core set may include measures unfamiliar to some researchers, so 
we have provided links to resources for training in Supplementary Table 2. Assessor training 
is required for good clinical practice, and standardization of training and certification protocols 
has been shown to reduce variance in scoring, thereby increasing power and reducing trial 
costs.54 We should note that this core set of measures may be insufficient to satisfy the needs 
for measuring outcomes for a specific stroke recovery or rehabilitation research question. Other 
outcomes may be added; however, we strongly recommend that researchers be judicious in 
their choice of additional measures, limit the number of outcomes assessed and identify, a 
priori, the primary outcome measure and power the trial accordingly. We recommend that 
researchers follow standards for recording adverse events in trials (e.g. falls, pain, etc.).55 
Since the SRRR meeting, we have expanded the current methods to include a more extensive 
list of outcomes (e.g. participation, depression, sensation, strength).  
Similarly, further recommendations for additional outcomes will follow for the use of 
kinematic and kinetic measures. However, adoption of the current recommendations outlined 
in this and other papers in this series would alone significantly advance the quality, 
reproducibility and rigor of stroke recovery and rehabilitation research. There is considerable 
urgency to do this. Results of most recent phase III and IV trials have been largely neutral or 
negative. At a time when funding for all clinical trials is undergoing unprecedented scrutiny, 
convincing funding bodies to commit to further trials will become more difficult in the absence 
of such self-imposed discipline. We must ensure that our trials are mechanistically well 
conceptualized, with careful matching of the nature of the intervention and the outcome 
measure chosen. A recent review of manuscript submissions to one of the major stroke journals 
found that ‘rehabilitation’ studies reached lower priority scores and were less likely to be 
accepted for publication.56 The authors hypothesized that inconsistencies in the described 
methodology and lower training of rehabilitation specialists in research methods would explain 
the findings. Adhering to agreed definitions, using standardized measures and reporting 
recommended outcomes would significantly improve the quality of stroke recovery trials.  
Our target was ambitious. Due to the currently limited evidence available, there remain gaps 
in our knowledge that hamper further progress. We do not know the best behavioral prognostic 
factors to include in stroke recovery trials, nor how to best stratify patients. While early ‘stroke 
severity’ is strongly predictive of functional outcome on a group level, other patient and stroke-
related factors will influence response to rehabilitation: we need to determine the most 
powerful prognostic factors of stroke recovery57–60 to optimize stratification.5,18 We have 
yet to determine which preclinical factors and other risk factors should be included in every 
stroke recovery trial, but better characterization of our patients, their stroke and their recovery 
will help us identify ‘recovery phenotypes’.  
We agreed that we need to objectively measure quality of motor performance using technology 
to help distinguish restitution and compensation, although we were unable to recommend a 
specific set of parameters at this stage. This step is vital to enhance current knowledge about 
heightened levels of plasticity and its interaction with motor learning early post stroke, and for 
trials seeking to test interventions targeting brain repair.61 Recovery trials should start early 
post stroke, and include both core clinical measures and kinematics assessed serially at standard 
intervals post stroke. Use of these measurement tools and methods of data synthesis and 
analysis in clinical trials are still in their infancy but are moving forward quickly as technology 
evolves. Providing recommendations in this area is a future target of our group.  
In this first step, our SRRR group targeted sensorimotor outcomes, not cognitive or other 
impairments that are the focus of other groups.8,9 While there is more to do in this field, the 
value and urgency of working towards standardized measurement, in clinical practice and in 
research, are indisputable. Stroke rehabilitation is a beacon of hope for stroke survivors, but 
stroke recovery is exceedingly complex and progress towards effective treatments has been 
frustratingly slow. Reasons for the slow progress are likely attributable to the noise introduced 
by under-conceptualized mechanistic frameworks and omissions of better ways to categorize 
our patients and our outcomes. As a research and clinical practice community, we need to work 
together to combine the latest concepts and findings in neuroscience and experimental 
psychology with sophisticated clinical trial methodologies and outcomes research.  
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